- Denali Therapeutics press release (NASDAQ:DNLI): Q2 GAAP EPS of -$0.72 in-line.
- Cash, cash equivalents, and marketable securities were approximately $977.4 million as of June 30, 2025.
Denali Therapeutics GAAP EPS of -$0.72 in-line

Related
Albemarle COO Johnson to leave company as part of restructur...
22 minutes ago
0
Trump says Intel CEO has ‘amazing story,’ sets Cabinet talks...
36 minutes ago
0
Oil Refineries Non-GAAP EPS of -$0.04, revenue of $59....
52 minutes ago
0
TPG announces pricing of senior notes
54 minutes ago
0
Exchange Income reports Q2 results
54 minutes ago
0
Quipt Home Medical GAAP EPS of -$0.07 in-line, revenue of $5...
58 minutes ago
0
Titanium Transportation Group reports Q2 results
1 hour ago
0
Anteris Technologies reports Q2 results
1 hour ago
0
Playboy Q2 2025 Earnings Preview
1 hour ago
0
Zevra Therapeutics Q2 2025 Earnings Preview
1 hour ago
0
Ecopetrol Q2 2025 Earnings Preview
1 hour ago
0
Navigator Holdings Q2 2025 Earnings Preview
1 hour ago
0
Trending
Popular
عکس | ماه کامل بر فراز حرم امام حسین (ع)
2 days ago
3
© FBT Company 2025. All rights are reserved